Lexicon Pharmaceuticals vs Rockwell Medical
LXRX and RMTI side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How LXRX and RMTI compare
Lexicon Pharmaceuticals is the larger company, worth 30 times as much as Rockwell Medical ($792M against $26.6M).
Rockwell Medical grew revenue faster over the last twelve months (−21.1% versus −29.0% for Lexicon Pharmaceuticals).
Rockwell Medical keeps more of each dollar of sales as profit, with a net margin of −7.3% compared with −147% at Lexicon Pharmaceuticals.
Rockwell Medical scores higher on the StockData Score (11 against 5 for Lexicon Pharmaceuticals), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | LXRX | RMTI |
|---|---|---|
| Size and price | ||
| Market cap | $792M | $26.6M |
| Share price | $1.78 | $6.61 |
| Change, 1 year | 19.5% | −28.1% |
| Change, 5 years | −62.4% | −86.3% |
| Beta (5Y) | 0.01 | 0.01 |
| Employees | 81 | 157 |
| StockData Score | ||
| Total score | 5 | 11 (better) |
| Valuation score | 0 | 3 (better) |
| Growth score | 1 | 1 |
| Performance score | 2 | 3 (better) |
| Health score | 2 | 4 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 19.1× | 0.4× (better) |
| P/B | 4.5× | 0.8× (better) |
| P/FCF | – | 17.3× |
| FCF yield | – | 5.8% |
| Fair value | $0.950 | $32.27 |
| Margin of safety | −87.4% | 79.5% (better) |
| Growth | ||
| Revenue growth (TTM) | −29.0% | −21.1% (better) |
| Revenue growth, 5Y average | 15.7% (better) | 2.2% |
| Profitability | ||
| Gross margin | 99.1% (better) | 17.7% |
| Operating margin | −131% | −6.5% (better) |
| Net margin | −147% | −7.3% (better) |
| FCF margin | – | 2.2% |
| Return on equity | −40.2% | −15.5% (better) |
| Return on invested capital | −163% | −17.9% (better) |
| Financial health | ||
| Debt / equity | 0.29 | 0.26 (better) |
| Interest coverage | – | −4.0× |
| Current ratio | 13.37 (better) | 3.25 |
| Altman Z-score | −4.87 (better) | −7.81 |
| Piotroski F-score | 4 (better) | 2 |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 81.9% | 0.05% |
| Held by insiders | – | 100% |
| Insider net buying, 12 months | $2.8M (better) | −$11.6K |
Go deeper
- LXRX stock overview
- LXRX income statement
- LXRX valuation and score
- RMTI stock overview
- RMTI income statement
- RMTI valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.